Niki BioSolutions, Inc. · NASDAQ:NIKI
Niki BioSolutions — Aptorum Group — Investor Presentation (May 2019)
12 slides from Niki BioSolutions's investor presentation, May 31, 2019
Slide 1: Aptorum Group
Lt P OCESSES yw SMART Ps < APTORUM GROUP (A080 PN
Slide 2: Nasdaq Listed
a we a i - s0.78%_ 10.50 200% 251.53 phobia le SM se2t 58508 On 18th December 2018, Aptorum Group Limited listed on the NASDAQ (ticker symbol: APM). IPO stock price is USD 15.80. Latest stock NasdaqListed . pice is over USD 28.00 with current market capital of over USD 800 M. 2 Foxman oreo
Slide 3: The Expanding Universe of Aptorum
‘The Expanding Universe of Aptorum 7 * Acticule: Non-Antibiotic Platform Claves: smart-Act: Pioneering Accelerating drug Druggable development via systematic drug Platform in microbiome repurposing for ‘orphan diseases BY Ever expanding universe of drug IP cont 208 poe itd v 3 Fortes puposes ony Tee
Slide 4: ACT- Accelerating the Commercialisation of Therapeutics
ACT- Accelerating the Commercialisation of Therapeutics PRECLINICAL TIME cost “12 YEARS? USD 2.6 BILLION? ‘opt nautaninnescaes, costly and high-sk business FAILURE RATE 86.2% nearly 86.2% of drug candidates entering phase 1 trials fails to achieve drug approval Forte pupeseson The sro panne ct anys
Slide 5: ACT- Accelerating the Commercialisation of Therapeutics
ACT- Accelerating the Commercialisation of Therapeutics —— ‘COMPUTATIONAL ALGORITHMS AND BIG DATA Protein docking, genetic simulation, immunology, ‘genomics, bioimaging, animal studies, proteomics COMPUTATIONAL, ‘ALGORITHMS & 1G ONT @ REPURPOSE Potentially skip preclinical and Phase | by Using exist
Slide 6: Traditional 3D & ACT 3D
TRADITIONAL 3D & ACT 3D Traditional 3D - Problems ‘Act 3D - Solutions 1017 years! Drug Discovery: 310 years* Time years) Precical Development: i year Phase I: Several months? Phase Il to market: 5.4 years! cost US62.6 lion’ Probabiiny —_Y Lewhitrate from discovery to commerclalistion ‘Snes cpt urea
Slide 7: Life Examples: Neuroblastoma
LIFE EXAMPLES: Neuroblastoma W drcsidemifed 2a crgs eid 2 dsideies Wet Lab Validation 2019 Phase 3 Trial Done 2001 Regulatory Approval 2008 Commercialisation 2025 Total 6 years” ‘err totam cf iin ant er naan es ‘Srrton ture esa aonegs autre sae aor at ene ieee Forte pupeseson The sro panne ct anys b
Slide 8: ACT- Accelerating the Commercialisation of Therapeutics
ACT- Accelerating the Commercialisation of Therapeutics
Slide 9: ACT- Accelerating the Commercialisation of Therapeutics
ACT- Accelerating the Commercialisation of Therapeutics —— i ein + 5 ~10%canites potently enter Sprite acne vation he inca aca year Pine ne oromucemoante/ amen se aotie it + bapet cin aset in 2020 aed io = ‘cumulatively ina asst! by 2023 6 200 Potential Asset + Projected midange value at Uss42 ~~ Pp
Slide 10: APM Stock Performance (as of 27/5/2019)
APM Stock Performance (as of 27/5/2019) ‘Announcement of Inclusion in MSCI Hong Kong Micro Cap Index Announcement of launching Claves Platform ‘Announcement of USD pA 90 M Agreement with | ASSTAR | ‘Announcement of launching Smart-Act™ —eP Platform 2019 feb mar ~ apr may TQ. Formas pots onh cient ca
Slide 11: eS eee
eS eee Certain information included in tis presentation and other statements or materials published by Aptorum Group Limited {the "Company") are not historical facts butare forward-looking statements. ‘These forward-looking statements refer in particular to the Company's management's business strate
Slide 12: Contact Us
CONTACT US sss § SMART PHARMA E info@smnhcom SWARTPHARMA ‘APTORUM GROUP a 1 499021176611 == Info@agtocungrun com APTORUM = * rec ittlcoagtenont W. snnwaptorumgroup com STAY IN TOUCH ‘ume/Smtpharma Plz] ‘edit. com/t/SmartPharma - ML medium comysmare-pharma A WV swivercomfsipharma S f Fin tntedncom/co